Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | STAT5B | P51692 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29252874 | 0.83 | STAT5B (0.33) | STAT5B | |
| SCHEMBL22207562 | 0.81 | KMT2A (0.34) | KMT2A | |
| SCHEMBL22207617 | 0.78 | GRIA1 (0.32) | STAT5BALDH1A1 | |
| SCHEMBL3482891 | 0.75 | STAT5B (0.38) | KMT2ASTAT5BALDH1A1 | |
| SCHEMBL24335090 | 0.74 | HTT (0.46) | KMT2AALDH1A1 | |
| SCHEMBL29224220 | 0.67 | — | — | |
| SCHEMBL1043406 | 0.67 | — | — | |
| SCHEMBL23989960 | 0.66 | CA12 (0.34) | STAT5B | |
| SCHEMBL23991175 | 0.66 | CA12 (0.34) | STAT5B | |
| SCHEMBL261709 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025202922-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-02 | — | — | WO | disclosed |
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | US | disclosed |
| EP-4525987-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12252491-B2 | IL-17A inhibitors | ELI LILLY AND COMPANY (US) | 2025-03-18 | — | — | US | disclosed |
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-24 | — | — | US | disclosed |
| WO-2024173173-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4408847-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| CN-118317962-A | Imidazopyridazine IL-17 inhibitor compounds | 詹森药业有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023049887-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| US-20220073526-A1 | IL-17A INHIBITORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| US-20220073526-A1 | IL-17A INHIBITORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| EP-3908585-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-11-17 | — | — | EP | disclosed |
| CN-113286795-A | Imidazo [1,2-b ] pyridazine IL-17A inhibitors | 伊莱利利公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | IL17A, IL23R, IL15 | KMT2A 2187/4885STAT5B 25/4885ALDH1A1 144/4885 |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | IL17A, IL15, IL18 | KMT2A 2426/4885STAT5B 45/4885ALDH1A1 392/4885 |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | KMT2A 2187/4885STAT5B 25/4885ALDH1A1 144/4885 |
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | KMT2A 2187/4885STAT5B 25/4885ALDH1A1 144/4885 |
| US-12252491-B2 | IL-17A inhibitors | IL17A, IL2, IL15 | KMT2A 1267/4885STAT5B 114/4885ALDH1A1 942/4885 |
| US-20220073526-A1 | IL-17A INHIBITORS | IL17A, IL2, IL15 | KMT2A 1267/4885STAT5B 114/4885ALDH1A1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.